# NAD+ Side Effects and Safety in the Research Literature | NAD+ > NAD+ side effects and safety: oral NMN/NR were well tolerated in trials; IV NAD+ is compounded and unapproved with a Class I endotoxin recall; the NMN FDA status is disputed, not banned. Cited. Oral precursors were well tolerated in trials. Injectable NAD+ is a different animal: compounded, unapproved, and the subject of a Class I recall for endotoxin. Here is the honest safety ledger. ## The short version On NAD+ side effects and safety, the literature splits cleanly by route. Swallowed precursors (NMN and NR — building blocks the body turns into NAD+) were well tolerated in the trials that tested them, with adverse-event rates close to placebo [4][9]. The route to worry about is the needle: intravenous and injectable NAD+ is a *compounded* wellness therapy (mixed by a pharmacy, not made by an FDA-approved manufacturer), it rests on very little controlled evidence, and one compounded product was pulled in a Class I recall — the most serious kind — for bacterial endotoxin contamination [18]. None of this is dosing advice. It is the safety record, kept in plain sight. ## Tolerability of oral precursors in the trials Where oral NMN and NR have been tested in randomized trials, the tolerability record is reassuring — within the bounds of what those trials measured. NR at 100, 300 and 1000 mg/day for 8 weeks in healthy overweight adults showed no significant adverse-event difference from placebo at any dose, no flushing, and no elevation of LDL cholesterol [4]. NMN at 250 mg/day for 12 weeks in healthy subjects produced no observed adverse effects, and blood NAD+ returned to baseline after stopping [9]. Even in patient populations the signal held: NR was safe in congestive-heart-failure patients at `1000 mg twice daily` for 21 days [7], and NR has been pushed to `3000 mg/day` in a Parkinson's-disease safety study. These are short-to-medium-term trials in selected populations, not open-ended safety guarantees — but they describe a well-tolerated profile for the oral precursors, which is exactly what the controlled human evidence is built on. ## Injectable and IV NAD+: An Unapproved Compounded Therapy Injectable and IV NAD+ is where the safety story changes. An NAD injection delivers NAD+ parenterally — straight into a vein or under the skin — bypassing the absorption problem that makes oral NAD+ ineffective. But this is a *compounded* wellness therapy: it is not FDA-approved, the controlled evidence behind it is minimal (mostly pilot and retrospective data), and infused NAD+ is rapidly cleared from plasma, with one pilot study finding near-complete plasma removal within roughly the first two hours of infusion [17]. Infusions run too fast can cause chest and abdominal discomfort, flushing and nausea. The hardest fact on this page: the FDA issued a **Class I recall** — its most serious category, reserved for products that can cause serious harm or death — of a compounded NAD+ injection for elevated bacterial endotoxin [18]. Compounded injectables carry real contamination and purity risk; injectable NAD+ should be understood as an unapproved compounded therapy with documented quality problems, not an approved treatment. ## The NMN regulatory dispute: contested, not banned One precursor sits inside an unresolved regulatory fight. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug, which has created marketplace uncertainty about how NMN can be sold [16]. Read this for what it is: a **marketplace dispute** over a product's regulatory category, not a finding that NMN is unsafe and not a consumer "ban." NAD+ and its precursors — including NMN — are not prohibited by WADA [19]. The point of flagging it here is due diligence: the status is unsettled, the dispute is ongoing, and anyone reading the literature should know the supplement-versus-drug question for NMN is contested rather than closed. ## Other documented concerns Two further caveats appear in the literature. First, supplement-grade products vary widely in purity and actual content, and third-party testing is not guaranteed [16] — the label and the contents are not always the same thing. Second, a theoretical, context-dependent concern: because NAD+ supports the metabolism of proliferating cells, raising it could in principle fuel existing cancers, and NAD+ has dual, context-dependent roles in oncology, so caution has been advised in cancer populations [16]. These are noted as documented concerns in the research, not as established harms — and as with everything here, the digest gives no dosing or administration instructions. ## What is the downside of taking NAD+? Reviews note that translation to hard clinical outcomes is unproven [15], that IV NAD+ rests on minimal controlled evidence, and that compounded injectables carry contamination risk — the FDA has issued a Class I recall of a compounded NAD+ injection for elevated endotoxin [18]. Oral precursors themselves were well tolerated in trials [4][9]. ## Is it safe to take NAD daily? Oral precursors were well tolerated in daily-dosing trials — for example NR at 100–1000 mg/day for 8 weeks with no significant adverse-event difference from placebo [4], and NMN at 250 mg/day for 12 weeks with no safety signals [9]. This describes research findings, not a recommendation, and no dosing guidance is given here. ## What is an NAD injection? An NAD injection delivers NAD+ parenterally, into a vein (IV) or under the skin. Injectable and IV NAD+ is a compounded wellness therapy, not FDA-approved, with limited controlled evidence and documented quality risks — including a Class I recall of a compounded NAD+ injection for elevated endotoxin [18]. ## When should you inject NAD+? Studies do not establish injection timing. Reported wellness protocols use multi-hour infusions, but no controlled trial defines an optimal schedule, and infused NAD+ is rapidly cleared from plasma anyway [17]. This digest gives no dosing or administration instructions of any kind. ## Is NAD safe? Oral NMN and NR were well tolerated in trials [4][9] and are not WADA-prohibited [19]. IV and compounded NAD+ carries contamination risk — a Class I endotoxin recall is on the record [18]. This summarizes research, not a safety endorsement, and gives no dosing advice. ## How long do NAD side effects last? Timing is study-specific. In tolerability reports, IV NAD+ infusion-related symptoms — flushing, chest or abdominal discomfort, nausea when run fast — resolved on completing the infusion. Oral-precursor trials reported few adverse events overall [4][9], and with NMN blood NAD+ itself returned to baseline within about 16 weeks of stopping [9]. --- The NAD+ hype screenshotted and stapled to its source — the precursor trials that genuinely raised blood NAD+ stamped confirmed, the hard-outcome claims stamped preliminary, oral precursors kept apart from the compounded IV NAD+ behind a Class I recall, and the contested NMN status read as a dispute, not a ban; no clinic behind this corkboard and nothing here dosed, infused, prescribed, or sold.